Adverse Effects Associated With Newer Diabetes Therapies: A Review Article. (April 2017)

• Record Type: Journal Article
• Authors: Akiyode, Oluwaranti F.; Adesoye, Adebola A.
• Other Names: Millares-Sipin Catherine A. guest-editor.
• Is Part Of: Journal of pharmacy practice. Volume 30:Number 2(2017:Apr.)
• Page Start: 238
• Page End: 244
• Publication Date: 2017-04
• Subjects: glucagon-like peptide 1 receptor agonists -- dipeptidyl peptidase-4 inhibitors -- sodium-glucose cotransporter 2 inhibitors -- new antidiabetic agents -- adverse effects; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1177/0897190015594732
• Languages: English
• ISSNs: 0897-1900

Abstract

The increasing number of newer type 2 diabetes therapies has allowed providers an increased armamentarium for the optimal management of patients with diabetes. In fact, these newer agents have unique benefits in the management of type 2 diabetes. However, they are also associated with certain adverse effects. This review article aims to describe the notable adverse effects of these newer antidiabetic therapies including the glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and the sodium-glucose cotransporter 2 inhibitors. The adverse effects reviewed herein include pancreatitis, medullary thyroid carcinoma, heart failure, gastrointestinal disturbances, renal impairment, and genitourinary infections. More clinical data are necessary to solidify the association of some of these adverse effects with the newer diabetes agents. However, it is important for health care practitioners to be well informed and prepared to properly monitor patients for these adverse effects.